HC Wainwright Cuts Evolus (NASDAQ:EOLS) Price Target to $13.00

Evolus (NASDAQ:EOLS) had its price objective cut by HC Wainwright from $20.00 to $13.00 in a report issued on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Evolus’ Q4 2025 earnings at $0.01 EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at $0.10 EPS, FY2028 earnings at $0.55 EPS, FY2029 earnings at $0.95 EPS and FY2030 earnings at $1.31 EPS.

A number of other equities research analysts also recently issued reports on the stock. Needham & Company LLC reissued a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. Mizuho lowered their target price on Evolus from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Monday, December 1st. Wall Street Zen raised Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Finally, BTIG Research lowered their price objective on Evolus from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Evolus has an average rating of “Moderate Buy” and an average price target of $17.50.

Evolus Stock Down 3.9%

Shares of NASDAQ:EOLS opened at $4.41 on Tuesday. The firm’s 50 day moving average price is $6.06 and its 200-day moving average price is $6.73. Evolus has a twelve month low of $4.41 and a twelve month high of $17.12. The stock has a market capitalization of $285.86 million, a PE ratio of -4.79 and a beta of 1.11.

Evolus (NASDAQ:EOLS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. The business had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million. Analysts expect that Evolus will post -0.61 earnings per share for the current fiscal year.

Insider Activity at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the company’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the transaction, the insider owned 354,388 shares of the company’s stock, valued at $2,533,874.20. This represents a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 5.90% of the stock is owned by insiders.

Institutional Trading of Evolus

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC boosted its stake in Evolus by 33.2% in the 3rd quarter. Nantahala Capital Management LLC now owns 5,726,857 shares of the company’s stock worth $35,163,000 after purchasing an additional 1,428,931 shares during the period. Caligan Partners LP lifted its holdings in shares of Evolus by 23.8% in the third quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock worth $25,413,000 after buying an additional 796,973 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Evolus by 3.3% during the third quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock worth $21,054,000 after acquiring an additional 110,693 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new position in Evolus during the second quarter valued at $22,431,000. Finally, Soleus Capital Management L.P. increased its holdings in Evolus by 96.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock valued at $19,516,000 after acquiring an additional 1,039,842 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.